Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCND2 | P30279 | 1/20 | 0.37 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272184 | 0.85 | LMNA (0.41) | LMNAKDM4EALDH1A1POLBHPGD | |
| SCHEMBL4652568 | 0.83 | DPP4 (0.50) | LMNAKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6197857 | 0.81 | KDM4E (0.39) | KDM4EALDH1A1GAAASPHKDM8 | |
| SCHEMBL6199950 | 0.81 | KDM4E (0.41) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL6083555 | 0.80 | KDM4E (0.40) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL27471079 | 0.78 | TET2 (0.40) | KDM4EHPGDHSD17B10ASPHKDM8 | |
| SCHEMBL21836559 | 0.76 | ALOX5AP (0.39) | KDM4EALDH1A1HPGDHSD17B10ASPH | |
| SCHEMBL3965438 | 0.76 | SLC2A1 (0.47) | KDM4E | |
| SCHEMBL6201203 | 0.75 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10ASPH | |
| SCHEMBL6148137 | 0.74 | LMNA (0.65) | LMNAKDM4EALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687276-B1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2009-10-14 | — | — | EP | disclosed |
| CN-100537540-C | Process for preparing 3-fluoroquinolines | AVENTIS PHARMA SA (FR) | 2009-09-09 | — | — | CN | disclosed |
| US-7396934-B2 | Process for preparing 3-fluoroquinolines | NOVEXEL (FR) | 2008-07-08 | — | — | US | disclosed |
| CN-1894216-A | Novel process for preparing 3-fluoroquinolines | AVENTIS PHARMA SA (FR) | 2007-01-10 | — | — | CN | disclosed |
| EP-1687276-A1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2006-08-09 | — | — | EP | disclosed |
| US-20050182259-A1 | Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound | AVENTIS PHARMA S.A. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005049575-A1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182259-A1 | Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound | QRFPR, NQO2, DHX35 | LMNA 4268/4885KDM4E 2535/4885ALDH1A1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.